SCHEMBL3132484

SCHEMBL3132484

O=C(O)c1cccc(N(Cc2cnccn2)c2ccc(OC(F)F)c(OC(F)F)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 4/20 0.39
SYK P43405 2/20 0.38
PDE4A P27815 4/20 0.38
PDE4B Q07343 3/20 0.38
PDE4C Q08493 3/20 0.38
MRGPRX4 Q96LA9 1/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
GAA P10253 1/20 0.36
KMO O15229 1/20 0.36
RXRA P19793 2/20 0.36
PPARA Q07869 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3126150 0.95 RXRA (0.43) PDE4DSYKPDE4APDE4BPDE4C
SCHEMBL3129425 0.93 SYK (0.38) PDE4DSYKPDE4APDE4BPDE4C
SCHEMBL3120621 0.91 PDE4A (0.40) PDE4DSYKPDE4APDE4BPDE4C
SCHEMBL3131858 0.90 PDE4D (0.52) PDE4DPDE4APDE4BPDE4CRXRA
SCHEMBL3129681 0.88 PDE4D (0.50) PDE4DPDE4APDE4BPDE4CRXRA
SCHEMBL3132792 0.87 KMT2A (0.36) PDE4DPDE4APDE4BPDE4CLMNA
SCHEMBL3126333 0.87 RXRA (0.48) PDE4DPDE4APDE4BPDE4CGAA
SCHEMBL4194672 0.85 PDE4D (0.40) PDE4DSYKPDE4APDE4BPDE4C
SCHEMBL3132346 0.85 SYK (0.40) SYKKMT2AGAARXRA
SCHEMBL3122655 0.85 SYK (0.40) SYKKMT2AGAARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B PDE4D 9/4885SYK 2747/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.